Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Colgate-Palmolive Company filings document a global consumer-products issuer with NYSE-listed common stock and registered debt securities. The company's 8-K reports cover earnings releases, the Strategic Growth and Productivity Program, reportable operating segment realignments, senior-note activity, debt-listing changes and governance events such as director elections and officer succession.
Proxy materials describe board elections, executive compensation, shareholder voting matters and strategic priorities tied to growth, efficiency and cash flow. The filings also identify registered securities, including common stock and multiple note series, and provide formal records for shareholder meetings, compensation arrangements and changes affecting listed note classes.
COLGATE PALMOLIVE CO director John P. Bilbrey reported routine equity compensation and updated holdings. He received a grant of 2,075 shares of Common Stock as an annual director stock grant under the issuer's incentive compensation plan, increasing his direct holdings to 39,820 shares. He also received an annual director stock option grant for 2,424 shares at an exercise price of $86.74 per share, expiring on May 11, 2034, which becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date. In addition, a separate entry reflects 4,719 shares of Common Stock held indirectly by a trust.
Colgate-Palmolive Company held its Annual Meeting of Stockholders on May 8, 2026. Stockholders elected ten directors, including Noel Wallace and nine other nominees, each receiving several hundred million votes in favor, with broker non-votes recorded on the election items.
Stockholders ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 647,385,500 votes for and 53,015,911 against. A non-binding advisory vote on executive compensation was approved, with 591,185,556 votes for and 43,039,011 against.
Two stockholder proposals were not approved. A proposal titled “Remove DEI from Board Candidate Considerations” received 14,002,273 votes for and 618,251,142 against. A proposal titled “Independent Board Chairman” received 182,439,869 votes for and 452,415,385 against.
Colgate-Palmolive Chief People Officer Sally Massey sold 8,599 shares of Common Stock in an open-market transaction. The sale took place on May 7, 2026 at a weighted average price of $87.4093 per share, with individual prices ranging from $87.36 to $87.53.
After the sale, Massey directly owned 13,785 shares of Colgate-Palmolive common stock and indirectly held 8,152 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive Company reported first-quarter 2026 Net sales of $5,324 million, up 8.4% from 2025, driven by 1.1% volume growth, 2.2% higher pricing and 5.1% positive foreign exchange. Organic sales grew 2.9%, with Oral, Personal and Home Care organic sales up 3.1% and Hill’s Pet Nutrition up 2.1%.
Gross profit rose to $3,226 million, though gross margin slipped to 60.6% as significantly higher raw and packaging material costs more than offset funding-the-growth savings and pricing. GAAP operating profit fell to $964 million, but on a non-GAAP basis increased 4% to $1,134 million, reflecting restructuring adjustments.
GAAP diluted EPS declined to $0.80 from $0.85, while non-GAAP diluted EPS increased to $0.97 from $0.91, helped by higher operating profit and share count changes. The Board expanded the Strategic Growth and Productivity Program, raising expected cumulative pre-tax charges to $350–$550 million and targeting annualized pre-tax savings of $200–$300 million by the end of 2028.
Colgate-Palmolive Company reported mixed first quarter 2026 results and expanded its Strategic Growth and Productivity Program. Net sales rose to $5,324 million, up 8.4% from $4,911 million, with organic sales up 2.9%. GAAP diluted EPS declined 6% to $0.80, while Base Business diluted EPS increased 7% to $0.97. Operating profit on a GAAP basis fell 10% to $964 million, but Base Business operating profit grew 4% to $1,134 million. Net cash provided by operations was $747 million, producing free cash flow before dividends of $609 million.
The Board approved an expansion of the Strategic Growth and Productivity Program, now expected to generate cumulative pre-tax charges of $350 million to $550 million, up from $200 million to $300 million, with 80% to 90% of these charges in cash and substantially all incurred by December 31, 2028. The program targets organizational changes and supply chain optimization across all regions and businesses. Colgate maintained its 2026 sales and EPS guidance but now expects gross profit margin to be down on both GAAP and Base Business bases.
Colgate-Palmolive Co reports a 13G filing showing 60,404,276 shares beneficially owned (7.52% of the class). The filing states Vanguard Capital Management has sole voting power for 8,184,452 shares and sole dispositive power for 60,404,276 shares.
The filing notes these holdings are reported on behalf of Vanguard-managed funds and accounts under Schedule 13G and were signed on 04/29/2026.
Colgate-Palmolive Company is planning a legal leadership transition. Jennifer M. Daniels, Chief Legal Officer and Secretary since 2014, has informed the company of her intention to retire in 2026. On April 8, 2026, the Board elected Betsy Fishbone, currently Executive Vice President and Deputy Chief Legal Officer, to become Chief Legal Officer and Secretary effective June 1, 2026. On the same date, the Board elected Ms. Daniels as Vice Chair of the company, also effective June 1, 2026, to support an orderly handover of her responsibilities to Ms. Fishbone.
NORRINGTON LORRIE M reported acquisition or exercise transactions in this Form 4 filing.
COLGATE PALMOLIVE CO director Lorrie M. Norrington received an equity award of 294 shares of Common Stock, valued at $89.05 per share. The award represents a portion of her annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, and increases her direct holdings to 40,160 shares.
Newman Brian reported acquisition or exercise transactions in this Form 4 filing.
Colgate-Palmolive director Brian Newman received 210 shares of Common Stock as a grant on April 1, 2026, at $89.05 per share. The award represents a portion of his annual cash retainer deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
After this grant, he directly holds 5,534 shares of Colgate-Palmolive Common Stock. In addition, 36 shares are held indirectly through a family trust. This filing reflects routine director compensation rather than an open-market purchase or sale.
Colgate-Palmolive director John P. Bilbrey acquired 266 shares of Common Stock as a compensation award. The shares, valued at $89.05 each, represent a portion of his annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
After this grant, he directly holds 37,665 Colgate-Palmolive shares and has an additional 4,719 shares held indirectly by a trust. The transaction reflects routine director compensation rather than an open-market purchase.